论文部分内容阅读
目的:探讨高通量血液透析在终末期肾病治疗中的应用价值。方法:随机选取2010年1月-2012年1月本院收治的肾病患者60例,根据患者就诊时间的先后,分为观察组与对照组,每组30例,均给予常规药物治疗,对照组患者行血液透析,观察组患者行高通量法血液透析,比较两组患者治疗后的β2微球蛋白(β2-MG)、C反应蛋白(CRP),血清白蛋白、血红蛋白情况。结果:观察组血红蛋白、血清白蛋白水平高于对照组(P<0.05);β2-Mg、CRP低于对照组,差异具有统计学意义(P<0.05)。结论:给予肾病患者行高通量血液透析,可提高血液透析效果,不过是否可改善患者终末期肾衰竭导致的胰岛素抵抗,需要进一步研究证实。
Objective: To investigate the value of high-flux hemodialysis in the treatment of end-stage renal disease. Methods: Sixty patients with nephropathy admitted to our hospital from January 2010 to January 2012 were randomly selected and divided into observation group and control group, 30 cases in each group were given conventional drug treatment and control group Patients underwent hemodialysis. Patients in the observation group underwent high-throughput hemodialysis. Β2-MG, CRP, serum albumin and hemoglobin were compared between the two groups after treatment. Results: The levels of hemoglobin and serum albumin in the observation group were higher than those in the control group (P <0.05). The levels of β2-Mg and CRP in the observation group were lower than those in the control group (P <0.05). Conclusion: High-throughput hemodialysis patients with renal disease can improve the hemodialysis effect, but whether to improve insulin resistance in patients with end-stage renal failure needs further study confirmed.